Moreover, the combined treatment of ACP52C and the CASP2 inhibiting peptide sensitized ACP52C‐resistant cancer cell lines (Figure 6I,J) and human primary tumor cells to ACP52C (Figure 6I; Figure S19, Supporting Information). Here, CASP2 is linked to neoplasm.